Literature DB >> 30613939

Advances in cellular and humoral immunotherapy - implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma.

Yaya Chu1, Aliza Gardenswartz1, Amanda M Termuhlen2, Mitchell S Cairo1,3,4,5,6.   

Abstract

Patients with relapsed, refractory or advanced stage B non-Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral-derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma on September 26th-29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.
© 2019 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  B-cell non-Hodgkin lymphoma; IL-15 superagonist; cellular immunotherapy; chimeric antigen receptor; stem cell transplantation

Mesh：

Year:  2019        PMID： 30613939      PMCID： PMC6555680          DOI： 10.1111/bjh.15753

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  97 in total

1.  Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT).

Authors:  R Fanin; M C Ruiz de Elvira; A Sperotto; M Baccarani; A Goldstone
Journal:  Bone Marrow Transplant       Date:  1999-03       Impact factor: 5.483

2.  Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.

Authors:  A M Carella; M Cavaliere; E Lerma; R Ferrara; L Tedeschi; A Romanelli; M Vinci; G Pinotti; P Lambelet; C Loni; S Verdiani; F De Stefano; M Valbonesi; M T Corsetti
Journal:  J Clin Oncol       Date:  2000-12-01       Impact factor: 44.544

3.  CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals.

Authors:  Dennis C Otero; Amy N Anzelon; Robert C Rickert
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

4.  A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.

Authors:  A Löffler; P Kufer; R Lutterbüse; F Zettl; P T Daniel; J M Schwenkenbecher; G Riethmüller; B Dörken; R C Bargou
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

Review 5.  Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis.

Authors:  Averil Ma; Rima Koka; Patrick Burkett
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

Review 6.  Tumour stem cells and drug resistance.

Authors:  Michael Dean; Tito Fojo; Susan Bates
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

7.  A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma.

Authors:  John E Levine; Richard E Harris; Fausto R Loberiza; James O Armitage; Julie M Vose; Koen Van Besien; Hillard M Lazarus; Mary M Horowitz; Asad Bashey; Brian J Bolwell; Linda J Burns; Mitchell S Cairo; Richard E Champlin; Cesar O Freytes; John Gibson; Steve C Goldstein; Mary J Laughlin; John Lister; David I Marks; Richard T Maziarz; Alan M Miller; Gustavo A Milone; Santiago Pavlovsky; Amdrew L Pecora; J Douglas Rizzo; Gary Schiller; Harry C Schouten; Mei Jie Zhang
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

8.  Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912.

Authors:  N L Kobrinsky; R Sposto; N R Shah; J R Anderson; C DeLaat; M Morse; P Warkentin; G S Gilchrist; M D Cohen; D Shina; A T Meadows
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

9.  Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

Authors:  Catherine M Bollard; Claudia Rössig; M Julia Calonge; M Helen Huls; Hans-Joachim Wagner; Joan Massague; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

10.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728
View more
  7 in total

Review 1.  Genetically engineered T cells for cancer immunotherapy.

Authors:  Dan Li; Xue Li; Wei-Lin Zhou; Yong Huang; Xiao Liang; Lin Jiang; Xiao Yang; Jie Sun; Zonghai Li; Wei-Dong Han; Wei Wang
Journal:  Signal Transduct Target Ther       Date:  2019-09-20

Review 2.  The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL).

Authors:  Yaya Chu; Margaret Lamb; Mitchell S Cairo; Dean A Lee
Journal:  Curr Treat Options Oncol       Date:  2022-03-08

3.  Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice.

Authors:  Yaya Chu; Gaurav Nayyar; Susiyan Jiang; Jeremy M Rosenblum; Patrick Soon-Shiong; Jeffrey T Safrit; Dean A Lee; Mitchell S Cairo
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

Review 4.  The Possibilities of Immunotherapy for Children with Primary Immunodeficiencies Associated with Cancers.

Authors:  Frederic Baleydier; Fanette Bernard; Marc Ansari
Journal:  Biomolecules       Date:  2020-07-28

5.  Novel cytokine-antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma.

Authors:  Yaya Chu; Gaurav Nayyar; Nang Kham Su; Jeremy M Rosenblum; Patrick Soon-Shiong; John Lee; Jeffrey T Safrit; Matthew Barth; Dean Lee; Mitchell S Cairo
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

Review 6.  Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma.

Authors:  Clifford M Csizmar; Stephen M Ansell
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

Review 7.  The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients.

Authors:  Justyna Derebas; Kinga Panuciak; Mikołaj Margas; Joanna Zawitkowska; Monika Lejman
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.